AstraZeneca’s Covid-19 vaccine is 80 per cent effective at preventing the disease in the elderly and does not increase the risk of blood clots, the biotech firm said Monday, following its US phase III efficiency trials.

It was 79 per cent effective at preventing symptomatic Covid-19 in the overall population and 100 per cent effective at preventing severe disease and hospitalization, it said.

Several countries had advised against administering the jab to older people due to a lack of data among elderly participants in previous trials. Earlier this month several countries also paused the use of the AstraZeneca shot over fears it may cause blood clots.

About the author


Writer !Artist Manager! Singer ! Accountant! PROMOTER

Leave a Comment

Open chat